GlobeNewsWire
30 Apr 2026, 20:01 UTC · 20w ago
Verdict
Headline takes no side. We score SNDX +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Syndax reported a 224% year-over-year increase in total first quarter 2026 revenue to $64.9 million.
More positive than 91% of claims this week
Topline data for axatilimab (Niktimvo) in Phase 2 trials for IPF and newly diagnosed chronic GVHD is expected in 4Q26.
So whatPositive results in these indications would significantly expand the addressable market and valuation of the drug.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 84% of claims this week
New real-world, frontline, and post-HSCT maintenance data for revumenib (Revuforj) is anticipated in 2Q26.
More positive than 76% of claims this week
The company reported a reduced net loss of $42.7 million for 1Q26 compared to $84.8 million in the prior year period.
More positive than 63% of claims this week
Syndax maintains a cash position of $352.1 million as of March 31, 2026.
So whatProvides a necessary liquidity cushion to fund ongoing pivotal trials and operations without immediate dilution.
More positive than 52% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2d ago
−17.8%
Price is moving against the score
$17.62 vs $21.43 close before publication (Apr 30) · not market-adjusted
SNDX chart →
